
Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’
An investor was hunting for new names to add to his “basket of busted biotech” companies when a deal caught his eye. The Carlyle Group, a private equity firm with $453 billion in assets under management, was buying bluebird bio for just under $50 million. …